Says to me that they had no take from the institutions at the $1.20 underwritten price inadvertently released to the market 2 weeks ago.
And us retail shareholders are given the opportunity to participate in $20m worth of the capital raising!
Admittedly this is at the edge of my understanding but wouldn't an alternative read be that they're confident and they've decided they can do better than $1.20? The plan is still for instos to make up the bulk of the raise .
Yup - someone has been pushing it up to facilitate the CR.
I am picking $1.00 as the placement price. What about others?
If share placement is going to be that low, shouldnt we see a large sell off right now and investors looking to rebuy as SP drops lower towards the SPP. There doesn't seem to be a large sell volume pending.
Don’t think so as they could not get the CR away 2 weeks ago at $1.20.
PEB is more optimistic overall this time though. They are aiming to raise a total of $80 million - not the $70m on the "incorrect" document published by the ASX.
"Don't be afraid to take a big step if one is indicated. You can't cross a chasm in two small jumps." David Lloyd George
If share placement is going to be that low, shouldnt we see a large sell off right now and investors looking to rebuy as SP drops lower towards the SPP. There doesn't seem to be a large sell volume pending.
Thoughts?
Trading halt.
Whatever is there will change dramatically depending on the price set by the CR.
PEB is more optimistic overall this time though. They are aiming to raise a total of $80 million - not the $70m on the "incorrect" document published by the ASX.
Start with this perhaps.
Consider as a guide to Kaisers involvement that they have about 1/27th of the population on their books.
Presentations of 7 million annually countrywide in the States for haematuria alone would leave Kaiser with roughly 1/27th of 7 million Triage evaluations which is 259,000 tests at roughly 1000NZD each.
This amounts to the entire capacity of the US operation at Hershey never mind the involvement for Monitor which for Kaiser would be 1/27th of 800,000 (around 30,000) patients requiring monitoring two or three times a year for 5 years. An extra 60-90,000 tests PA.
The base figures are on the FY results presentation.
Not intending to suggest that all would be forthcoming but it at least gives you some idea of the scale of it all when we only consider 1/27th of the population which is Kaisers share.
The trouble with that example is that it highlights that the current throughput is nothing to shout about. If it were even at a fraction of capacity one would think there would be no need for a raise. They're expecting to burn some cash...
The trouble with that example is that it highlights that the current throughput is nothing to shout about. If it were even at a fraction of capacity one would think there would be no need for a raise. They're expecting to burn some cash...
Yes but look at the amount of cash burn Xero expended before it was cash flow positive all beit from a lower base !
Bookmarks